The Effects of dapagliflozin in patients with type 2 Diabetes in a rural hospital in South India
Not Applicable
Completed
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Registration Number
- CTRI/2023/04/051669
- Lead Sponsor
- THE SCHIEFFELIN INSTITUTE OF HEALTH-RESEARCH AND LEPROSY CENTER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects should be at least 18 years of age
Known to have T2DM for more than one year
On Dapagliflozin for a minimum of 6 months
Exclusion Criteria
Gestational Diabetes
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood Pressure – Systolic and Diastolic <br/ ><br>FBS, PPBS, HbA1C, LDL <br/ ><br>Timepoint: Baseline and 6 and 12 months
- Secondary Outcome Measures
Name Time Method Estimated Glomerular Filtration Rate, Creatinine <br/ ><br>Body weight <br/ ><br>Documented side effects of Dapagliflozin <br/ ><br>Timepoint: Baseline and 6 and 12 months